{"DataElement":{"publicId":"4786479","version":"1","preferredName":"Patient CD4 Antigen And Antiviral Agent Administered Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the eligibility criteria for enrollment in a clinical trial with regards to CD4 antigen count and antiviral agent administration.","longName":"CD4_XVIR_AGT_ADM_IND","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"4786477","version":"1","preferredName":"Patient CD4 Antigen And Antiviral Agent Administered Clinical Trial Eligibility Criteria","preferredDefinition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._CD4 Antigen, encoded by the CD4 gene, is a T-cell surface glycoprotein. CD4 has a role in cell-cell interactions and may act in signal transduction. CD4 is a accessory protein for MHC class-II antigen/T-cell receptor interaction and functions to initiate or augment the early phase of T-cell activation. CD4 enhances T-cell sensitivity to antigen and binds to LCK, which phosphorylates CD3-zeta. CD4 Antigen also serves as an HIV receptor, binding directly to the envelope protein gp120 on HIV. (From LocusLink, OMIM and NCI)_An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence._Drugs used to treat infections caused by viruses._The act of having given something (e.g., a medication or test)._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"2233604v1.0:4786475v1.0","context":"Theradex","contextVersion":"1","ObjectClass":{"publicId":"2233604","version":"1","preferredName":"Patient","preferredDefinition":"A person who requires medical care.","longName":"C16960","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D847-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"4786475","version":"1","preferredName":"CD4 Antigen And Antiviral Agent Administered Clinical Trial Eligibility Criteria","preferredDefinition":"CD4 Antigen, encoded by the CD4 gene, is a T-cell surface glycoprotein. CD4 has a role in cell-cell interactions and may act in signal transduction. CD4 is a accessory protein for MHC class-II antigen/T-cell receptor interaction and functions to initiate or augment the early phase of T-cell activation. CD4 enhances T-cell sensitivity to antigen and binds to LCK, which phosphorylates CD3-zeta. CD4 Antigen also serves as an HIV receptor, binding directly to the envelope protein gp120 on HIV. (From LocusLink, OMIM and NCI):An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.:Drugs used to treat infections caused by viruses.:The act of having given something (e.g., a medication or test).:Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"4786475v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"T-Cell Surface Glycoprotein CD4","conceptCode":"C16300","definition":"T-cell surface glycoprotein CD4 (458 aa, ~51 kDa) is encoded by the human CD4 gene. This protein plays a role in antigen recognition and HIV entry.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Antiviral Agent","conceptCode":"C281","definition":"Any agent that can treat or prevent viral infections by interfering with the viral replication cycle.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"133E88EC-0FCB-8F43-E050-BB89AD4364A0","latestVersionIndicator":"Yes","beginDate":"2015-04-08","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-04-08","modifiedBy":"ONEDATA","dateModified":"2015-04-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"133E88EC-0FDC-8F43-E050-BB89AD4364A0","latestVersionIndicator":"Yes","beginDate":"2015-04-08","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-04-08","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"9008_Theradex_04.08.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3298541","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"Indicator to represent a response of Yes, No, or Not Applicable._The affirmative response to a question or activity._The non-affirmative response to a question._Determination that a value is not relevant in the current context._A system of numbered categories for representation of data.","longName":"YES_NO_NA_CD_IND","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"1","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"X","valueDescription":"Not applicable","ValueMeaning":{"publicId":"2581003","version":"1","preferredName":"Not applicable","longName":"2581003v1.00","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0978-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"CLOHNES","dateModified":"2023-11-09","changeDescription":null,"administrativeNotes":"2023.3.6 Added Alt VM-COG. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C223-0627-E040-BB89AD432C31","beginDate":"2002-02-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"N","valueDescription":"No","ValueMeaning":{"publicId":"2559515","version":"1","preferredName":"No","longName":"2559515","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B588-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2024-01-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C22D-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"Y","valueDescription":"Yes","ValueMeaning":{"publicId":"2560453","version":"1","preferredName":"Yes","longName":"2560453","preferredDefinition":"The affirmative response to a question or activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B932-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CLOHNES","dateModified":"2023-09-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C237-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3298540","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"The affirmative response to a question or activity.:The non-affirmative response to a question.:Determination that a value is not relevant in the current context.:A system of numbered categories for representation of data.:An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"3298540v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C1F2-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CTMS:Clinical Trials Monitoring Service","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C203-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"MAESKEB","dateModified":"2016-01-20","changeDescription":"Created to support Theradex design of CRFs for NCI CCR trials","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3876352","version":"1","longName":"Inclusion Criteria","context":"Theradex","ClassificationSchemeItems":[{"publicId":"3876425","version":"1","longName":"Laboratory Data (including serologic/viral status)","context":"Theradex"}]}],"AlternateNames":[{"name":"Theradex","type":"USED_BY","context":"Theradex"}],"ReferenceDocuments":[{"name":"Theradex - 1","type":"Alternate Question Text","description":"If patient is HIV positive, is CD4 count greater than 250/mm3 and patient is NOT receiving agents with the potential of PK interactions with romidepsin or hepatotoxic antiretroviral?","url":null,"context":"Theradex"},{"name":"If patient is HIV positive, i","type":"Preferred Question Text","description":"If patient is HIV positive, is CD4 count greater than 250/mm3 and patient is NOT receiving agents with the potential of PK interactions with romidepsin or hepatotoxic antiretroviral or do all PI based regimens?","url":null,"context":"Theradex"},{"name":"Theradex - 3","type":"Alternate Question Text","description":"If patient is HIV infected (positive), patient has no history of AIDS defining illness other than historic CD4+ T cell nadir of less than 200/mm3?","url":null,"context":"Theradex"},{"name":"Theradex - 2","type":"Alternate Question Text","description":"If patient is HIV positive, patient has no prior AIDS defining condition other than CD4+ cells nadir less than 200/mm3, pre-leukemia CD4+ count greater than or equal to 250/mm3 and patient is willing to adhere to antiretroviral therapy regimen with minimal overlapping toxicity and PK interactions with the experimental agents in this study?","url":null,"context":"Theradex"},{"name":"Theradex - 4","type":"Alternate Question Text","description":"If patient is HIV+, is CD4 count greater than or equal to 250 cells/mm3 and patient is on anti-viral therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 6","type":"Alternate Question Text","description":"If HIV positive, is patient on a stable dose of highly anti-retroviral therapy, requiring no concurrent antibiotics or antifungal agents for the prevention of opportunistic infections and the CD4 count is above  250 cells/mcl and an undectable HIV viral load on a standard PCR-based test?","url":null,"context":"Theradex"},{"name":"Theradex - 7","type":"Alternate Question Text","description":"If patient is HIV positive, are they stable on their anti-retroviral regimen, is healthy from an HIV perspective, has an undetectable viral load, CD4 count is greater than 250 cells/mcL, and patient is not receiving prophylactic therapy for an opportunistic infection?","url":null,"context":"Theradex"},{"name":"Theradex - 8","type":"Alternate Question Text","description":"If patient is HIV-positive is patient on a stable regimen of highly active anti-retroviral therapy (HAART), has no requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infection, CD4 count is above 250 cells/mcL and has an undetectable HIV viral load on standard PCR-based test?","url":null,"context":"Theradex"},{"name":"Theradex - 9","type":"Alternate Question Text","description":"If patient is HIV positive, are they stable on their anti-retroviral regimen and  healthy from an HIV perspective, CD4 count is greater than 250 cells/mcL, is not receiving prophylactic therapy for an opportunistic infection, is on antiretroviral therapy with be minimal interactions or overlapping toxicity of the antiretroviral therapy with the experimental cancer treatment and HIV viral load is less than 200 copies/mm3 by standard clinical assays?","url":null,"context":"Theradex"},{"name":"Theradex - 11","type":"Alternate Question Text","description":"If patient is HIV-positive is patient on a stable regimen of highly active anti-retroviral therapy (HAART) that does not include strong inhibitors and strong or moderate inducers of CYP3A4, has no requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infection, CD4 count is above 250 cells/mcL and patient has an undetectable HIV viral load on standard PCR-based test?","url":null,"context":"Theradex"},{"name":"Theradex - 13","type":"Alternate Question Text","description":"If patient is positive for HIV, is patient on a stable regimen of highly active anti-retroviral therapy (HAART) using combination retroviral agents which are not CYP3A4 inducers or inhibitors, there is no requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections and CD4 count is above 250 cells/mcL and an undetectable HIV viral load on standard PCR-based tests?","url":null,"context":"Theradex"},{"name":"Theradex - 14","type":"Alternate Question Text","description":"If patient is HIV+, is CD4+ count greater than or equal to 250 cells/mm3, viral load is negligible and patient is on a stable combination antiretroviral therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 15","type":"Alternate Question Text","description":"If patient is HIV-positive, is patient on a stable antiretroviral regimen, CD4 count is above 250 cells/mcL and has negative viral loads on standard PCR-based test?","url":null,"context":"Theradex"},{"name":"Theradex - 18","type":"Alternate Question Text","description":"Is patient HIV-positive and has a detectable viral load and/or CD4 count less than or equal to 300?","url":null,"context":"Theradex"},{"name":"Theradex - 17","type":"Alternate Question Text","description":"Is patient HIV-positive and has a detectable viral load and/or CD4 count greater than or equal to 300?","url":null,"context":"Theradex"},{"name":"Theradex - 16","type":"Alternate Question Text","description":"If patient is HIV positive, are they on a stable regimen of HAART, there is no requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections, CD4 count is greater than 250 cells/mcL, and patient has an undetectable HIV viral load on standard PCR-based tests?","url":null,"context":"Theradex"},{"name":"Theradex - 19","type":"Alternate Question Text","description":"If patient is HIV positive, are they on a stable antiretroviral regimen, CD4 count is greater than 250 cells/mcL and patient has a negative viral load?","url":null,"context":"Theradex"},{"name":"Theradex - 20","type":"Alternate Question Text","description":"If patient is HIV-positive, is patient on a stable antiretroviral regimen, CD4 count is above 250 cells/mcL and has negative viral loads?","url":null,"context":"Theradex"},{"name":"Theradex - 21","type":"Alternate Question Text","description":"If patient is known to be HIV positive, is CD4 count greater than 350 cells/mm3, viral load is undetectable, patient is maintained on modern therapeutic regimens utilizing non-CYP-interactive agents, and has no history of AIDS-defining opportunistic infections?","url":null,"context":"Theradex"},{"name":"Theradex - 22","type":"Alternate Question Text","description":"If patient is HIV-infected, is CD4 count greater than or equal to 250 cells/mcL over the past 6 months on this same anti-retroviral regimen and has not had a CD4 count less than 200 cells/mcL over the past 2 years, unless it was deemed related to the cancer and/or chemotherapy-induced bone marrow suppression?","url":null,"context":"Theradex"},{"name":"Theradex - 23","type":"Alternate Question Text","description":"If patient is HIV-positive, is disease well-controlled, as determined by CD4 count and viral load, and on antiretroviral therapy that does not contain a strong inducer or inhibitor of CYP3A4?","url":null,"context":"Theradex"},{"name":"Theradex - 24","type":"Alternate Question Text","description":"If patient is Human immunodeficiency virus (HIV)-infected, is patient stable on their anti-retroviral regimen, and healthy from an HIV perspective, CD4 count is greater than 250 cells/mcL and is not receiving prophylactic therapy for an opportunistic infection?","url":null,"context":"Theradex"},{"name":"Theradex - 12","type":"Alternate Question Text","description":"If patient is HIV positive, does patient have an undetectable HIV viral load by standard clinical assay within 6 months of registration, is willing to adhere to antiretroviral therapy that has minimal overlapping toxicity or pharmacokinetic interactions with protocol therapy, has not had AIDS-defining events within the past 12 months, has near normal life expectancy if not for the presence of the cancer and is not on HIV medications considered to be strong inhibitors or inducers of CYP3A4?","url":null,"context":"Theradex"}],"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"133E88EC-0FF5-8F43-E050-BB89AD4364A0","latestVersionIndicator":"Yes","beginDate":"2015-04-08","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-04-08","modifiedBy":"SOKKERL","dateModified":"2020-12-31","changeDescription":"9008_Theradex_04.08.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}